Thermo Fisher Scientific (NYSE:TMO) Issues Earnings Results

Thermo Fisher Scientific (NYSE:TMO) posted its quarterly earnings results on Thursday. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19, FiscalAI reports. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business posted $5.15 earnings per share. Thermo Fisher Scientific updated its FY 2026 guidance to 24.640-25.120 EPS.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher raised full‑year guidance, now targeting $47.3B–$48.1B in revenue (6%–8% reported) and $24.64–$25.12 adjusted EPS (8%–10% growth), still assuming 3%–4% organic growth.
• Completed the ~\$9 billion acquisition of Clario, which added \$30M of revenue and \$0.01 of adjusted EPS in Q1 and is expected to contribute roughly \$900M of revenue and \$0.32 of EPS to 2026 guidance.
• Delivered a strong Q1 with \$11.01B revenue (+6%), adjusted operating income of \$2.4B (+6%) and adjusted EPS of \$5.44 (+6%), while returning capital via \$3B of buybacks and a 10% dividend increase.
• Headwinds persist from tariffs, FX and potential higher inflation (company cites a placeholder for inflation risk), and Analytical Instruments faced softness (organic -2%) with a 250 bps margin decline; China and academic/government end markets remain muted.
• Company highlighted continued innovation and commercial momentum—new product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis, Gibco CTS Compleo), AI collaborations with Nvidia/OpenAI, and share gains in clinical research and bioproduction.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $53.47 during midday trading on Thursday, reaching $460.51. 2,661,263 shares of the stock traded hands, compared to its average volume of 2,274,602. The stock has a market cap of $171.14 billion, a P/E ratio of 25.95, a PEG ratio of 2.72 and a beta of 0.97. Thermo Fisher Scientific has a 12 month low of $385.46 and a 12 month high of $643.99. The stock’s fifty day moving average is $500.69 and its 200-day moving average is $550.56. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were given a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.60%.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 beat — Thermo Fisher posted adjusted EPS of $5.44 and revenue of $11.01B, topping consensus and showing 6.2% year-over-year sales growth; bottom-line and top-line beats are supportive for near-term earnings credibility. Q1 Earnings & Revenues Top Estimates
• Positive Sentiment: Analyst support — Some sell-side analysts remain constructive (Buy reiterations highlight confidence in core growth, reshoring and AI-related opportunities), which can limit downside versus peers. Buy Rating Reiterated
• Neutral Sentiment: Guidance published — Management updated FY2026 guidance to an EPS range of 24.640–25.120 and revenue $47.3B–$48.1B; the range broadly brackets consensus but the midpoint is marginally below some expectations, leaving room for interpretation by investors. Company Press Release
• Negative Sentiment: Muted underlying growth & cautious tone — Commentators flagged that underlying organic growth was muted and management’s commentary remained cautious even after a revenue upgrade, which undercut enthusiasm despite the beat. This narrative drove selling pressure. Thermo Fisher falls after earnings top estimates, but growth concerns persist
• Negative Sentiment: Mixed segment performance — Strength in lab products and biopharma services was offset by softness in analytical instruments and specialty diagnostics, raising execution/questions about sustainability of growth across the business. Market reaction showed a pre-/post-market decline despite the beat. Reuters: Quarterly Results Beat

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares of the company’s stock, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

A number of institutional investors have recently bought and sold shares of TMO. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth about $28,000. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Birchwood Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Osterweis Capital Management Inc. boosted its holdings in Thermo Fisher Scientific by 151.4% during the 3rd quarter. Osterweis Capital Management Inc. now owns 88 shares of the medical research company’s stock valued at $43,000 after acquiring an additional 53 shares during the period. Finally, Wealth Watch Advisors INC purchased a new stake in Thermo Fisher Scientific in the third quarter worth $44,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. Stifel Nicolaus upped their target price on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a report on Friday, January 9th. UBS Group restated a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. TD Cowen dropped their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Barclays decreased their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Finally, DZ Bank initiated coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $631.25.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.